Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10390 in IgA Nephropathy
NCT06635772Phase 2Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HS-10390 in IgA nephropathy (IgAN), sponsored by Hansoh Pharmaceutical Group. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
HS-10390
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06635772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06635772.